Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 12/20 | 0.63 |
| ▸ | KDM4A | O75164 | 1/20 | 0.58 |
| ▸ | KDM4B | O94953 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 2/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | ABL2 | P42684 | 1/20 | 0.58 |
| ▸ | VCP | P55072 | 4/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TERT | O14746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL794027 | 1.00 | FBP1 (0.63) | FBP1KDM4AKDM4BEGFRABL1 | |
| SCHEMBL807786 | 0.84 | VCP (0.61) | FBP1EGFRABL1ABL2VCP | |
| SCHEMBL793479 | 0.84 | VCP (0.66) | FBP1EGFRABL1ABL2VCP | |
| SCHEMBL1976021 | 0.84 | FBP1 (0.58) | FBP1EGFRABL1ABL2VCP | |
| SCHEMBL13773077 | 0.84 | EGFR (0.72) | FBP1EGFRABL1ABL2VCP | |
| SCHEMBL793577 | 0.84 | FBP1 (0.58) | FBP1EGFRABL1ABL2VCP | |
| SCHEMBL807974 | 0.84 | VCP (0.66) | FBP1EGFRABL1ABL2VCP | |
| SCHEMBL560425 | 0.84 | VCAM1 (0.67) | FBP1KDM4AKDM4BEGFRABL1 | |
| SCHEMBL793177 | 0.84 | VCP (0.61) | FBP1EGFRABL1ABL2VCP | |
| SCHEMBL8010226 | 0.84 | EGFR (0.72) | FBP1EGFRABL1ABL2VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109280030-B | Benzazaylalkyl aryl piperazine derivative and application thereof in preparing medicines | 江苏恩华药业股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-9346786-B2 | Pyrrolidine compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9226916-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9206124-B2 | Treatment of drug-resistant cancer with 2-aryl-2-(3-indolyl) acetohydroxamates | NEW MEXICO TECHNICAL RESEARCH FOUNDATION (US) | 2015-12-08 | — | — | US | disclosed |
| EP-2513084-B1 | PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-07-22 | — | — | EP | disclosed |
| US-20150105439-A1 | TREATMENT OF DRUG-RESISTANT CANCER WITH 2-ARYL-2-(3-INDOLYL) ACETOHYDROXAMATES | NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION | 2015-04-16 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| EP-2513052-B1 | PYRROLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-06-04 | — | — | EP | disclosed |
| EP-1905774-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-04-02 | — | — | EP | disclosed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| US-5455263-A | Administering substituted arylpyrrole compounds | AMERICAN CYANAMID COMPANY (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0347488-B1 | Arylpyrrole insecticidal acaricidal and nematicidal agents and method for the preparation thereof | AMERICAN CYANAMID CO (US) | 1994-06-01 | — | — | EP | disclosed |
| US-5310938-A | Miticides, insecticides, parasiticides, and anthelmintics | AMERICAN CYANAMID COMPANY (US) | 1994-05-10 | — | — | US | disclosed |
| EP-0312723-B1 | Method of and bait compositions for controlling mollusks | AMERICAN CYANAMID CO (US) | 1993-12-22 | — | — | EP | disclosed |
| US-5010098-A | Arylpyrrole insecticidal acaricidal and nematicidal agents and methods for the preparation thereof | AMERICAN CYANAMID COMPANY (US) | 1991-04-23 | — | — | US | disclosed |
| US-4929634-A | ARYLPYRROLE COMPOUNDS | AMERICAN CYANAMID COMPANY (US) | 1990-05-29 | — | — | US | disclosed |
| EP-0358047-A2 | Method of controlling phytopathogenic fungi | AMERICAN CYANAMID COMPANY (US) | 1990-03-14 | — | — | EP | disclosed |
| EP-0347488-A1 | Arylpyrrole insecticidal acaricidal and nematicidal agents and method for the preparation thereof | AMERICAN CYANAMID COMPANY (US) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105439-A1 | TREATMENT OF DRUG-RESISTANT CANCER WITH 2-ARYL-2-(3-INDOLYL) ACETOHYDROXAMATES | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCC1 | FBP1 4633/4885KDM4A 3104/4885KDM4B 3068/4885 |
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | FBP1 1093/4885KDM4A 3780/4885KDM4B 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.